10x Genomics, Inc. - Common Stock (TXG)

10x Genomics (TXG) Q4 2025 Earnings Transcript

Biotech company 10x Genomics (NASDAQ:TXG) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, but sales were flat year on year at $166 million. The company expects the full year’s revenue to be around $612.5 million, close to analysts’ estimates. Its GAAP loss of $0.13 per share was 37.5% above analysts’ consensus estimates.

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings this Thursday after market hours. Here’s what investors should know.

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Illumina (NASDAQ:ILMN) and its peers.

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 21.1% gain over the past six months, beating the S&P 500 by 10.6 percentage points.

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 4.7% in the afternoon session after the company announced weak preliminary results for its fourth quarter and full year 2025, which pointed to a significant drop in equipment sales. 

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a strategic collaboration with 10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, to establish ImmuneScape™, a multiomics research initiative designed by CareDx to elucidate the biology of transplant organ rejection and therapeutic response. Insights generated from this program are intended to support future clinical diagnostic development.

Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 2.5% in the afternoon session after several analysts raised their price targets on the stock, pointing to a more optimistic outlook for the life sciences sector. 

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 4.8% in the morning session after Canaccord Genuity maintained its 'Buy' rating and raised its price target on the company's shares. 

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.

10x Genomics (TXG) Q2 2025 Earnings Transcript

10x Genomics (TXG) Q4 2024 Earnings Transcript

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 6.3% in the morning session after Citigroup downgraded the stock to Neutral from Buy. 

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how life sciences tools & services stocks fared in Q3, starting with 10x Genomics (NASDAQ:TXG).

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

10x Genomics (TXG) Q3 2025 Earnings Transcript

A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies. These subsidies, which are government financial aids to help people pay for health insurance, are crucial for insurers as they maintain a stable customer base. An extension would ensure continued revenue for companies with significant exposure to the ACA marketplace. The news prompted a strong positive reaction from investors, with Centene (CNC) shares jumping as much as 8%, Molina Healthcare (MOH) rising over 3%, and Oscar Health (OSCR) soaring 18%. The potential for a two-year extension reduces regulatory uncertainty for the sector, which investors view as a significant positive for the industry's outlook.